SU14813
Catalog No. A11557
SU14813是一种口服多靶向酪氨酸激酶抑制剂(TKI)，靶向血管内皮生长因子受体(VEGFR)、血小板衍生生长因子受体(PDGFR)、KIT和fms样酪氨酸激酶3 (FLT-3)，抑制 VEGFR2，VEGFR1，PDGFRβ and KIT 的 IC50 值分别为50，2，4，15 nM。
| Catalog Num | A11557 |
|---|---|
| M. Wt | 442.48 |
| Formula | C23H27FN4O4 |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 627908-92-3 |
| Synonyms | SU14813; SU 14813; SU-14813 |
| SMILES | CC1=C(NC(=C1C(=O)NC[C@@H](CN2CCOCC2)O)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O |
SU14813是一种口服多靶向酪氨酸激酶抑制剂(TKI)，靶向血管内皮生长因子受体(VEGFR)、血小板衍生生长因子受体(PDGFR)、KIT和fms样酪氨酸激酶3 (FLT-3)，抑制 VEGFR2，VEGFR1，PDGFRβ and KIT 的 IC50 值分别为50，2，4，15 nM。
| In vitro | DMSO | 79 mg/mL (178.53 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 22.6 mL | 113 mL | 226 mL |
| 0.5 mM | 4.52 mL | 22.6 mL | 45.2 mL |
| 1 mM | 2.26 mL | 11.3 mL | 22.6 mL |
| 5 mM | 0.45 mL | 2.26 mL | 4.52 mL |
*The above data is based on the productmolecular weight 442.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.